EP2925350

BRISTOL-MYERS SQUIBB COMPANY
Application Number
EP13811698A
Filing Date
Dec 3, 2013
Status
Opposition Rejected
Sep 17, 2021
Grant Date
Jan 30, 2019
External Links
Slate, Register

Biblio Summary

The patent EP2925350B1 was granted on Jan 30, 2019 by Bristol-Myers Squibb Company The patent is currently Opposition Rejected.

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

PLOUGMANN VINGTOFT A/SOct 29, 2019ADMISSIBLE

The table below shows the patents of Bristol-Myers Squibb Company that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3631454Treatment Of Lag-3 Positive TumorsSep 13, 20232
EP3559230Methods For Increasing The Efficiency Of Homology Directed Repair (Hdr) In The Cellular GenomeSep 6, 20232
EP3227333Bispecific Antibodies Against Cd3Epsilon And Bcma For Use In Treatment Of DiseasesAug 16, 20233